Ajibade O Ashaye

Abstract In the Phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy and comparable safety profile versus imatinib in adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Here we report patient-reported outcomes (PRO) from PhALLCON assessed as exploratory endpoints using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) and EQ-5D-5L.

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), which represents around 30% of all adult ALL cases [1,2], previously had a very poor prognosis with a 1-year overall survival (OS) of around 10% on traditional chemotherapy [3]. Clinical outcomes improved significantly following the identification of the BCR-ABL1 oncogene, along with the introduction of the tyrosine kinase inhibitors (TKIs) imatinib and later second-generation TKIs such as dasatinib and bosutinib [3,4].

Background Atrial fibrillation (AF) is a common arrhythmia that presents a significant morbidity and mortality risk.1 Direct oral anticoagulants (DOACs) have been licensed and recommended for the prevention of stroke and systemic embolism in people with AF2–5 and are now favored over vitamin K antagonists for stroke prevention due to their superior safety profile.6 However, strokes and systemic embolism may still occur while receiving therapeutic anticoagulation and major bleeding is the most...